

## REMARKS

Applicants have amended the pending claims to add new claims 50-53. Upon entry of this amendment, claims 1-53 are pending in this application.

Support for new claims 50-53 can be found throughout the specification and in the claims as originally filed.

For example, support for the term “a prionopathy” is found at least at page 10, lines 16-25. Support for the term “a predisposition thereto” recited in new claim 1 can be found in the specification at least at page 2, line 19. Support for the term “located in said ocular tissue and imaging said ocular tissue” recited in new claim 1 can be found in the specification at least at page 5, lines 13-16; page 6, line 18; and page 8, lines 22-24. Support for the term “and allowing said compound to distribute into the lens” is found at least at page 8, line 9 of the specification. Support for the term “wherein said detectably-labeled compound is lipophilic” recited in new claim 1 can be found in the specification at least at page 9, lines 8 and 10-13.

Support for new claims 51 and 53 can be found in the specification at least at page 16, lines 23-25.

Support for the term “a prionopathy” recited in new claim 52 is found at least at page 10, lines 16-25. Support for the term “imaging said ocular tissue” recited in new claim 52 can be found in the specification at least at page 8, lines 19-24. Support for the term “and allowing said compound to distribute into the lens” is found in the specification at least at page 8, line 9. Support for the term “wherein said compound comprises a fluorophor” recited in new claim 52 can be found in the specification at least at page 3, lines 6-9. Likewise, support for the term “wherein said compound is lipophilic” recited in new claim 52 can be found in the specification at least at page 9, lines 8 and 10-13.

Goldstein, et al.  
U.S.S.N. 10/715,776

### CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and remark, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Christina K. Stock", is written over a horizontal line.

Ingrid A. Beattie, Reg. No. 42,306  
Christina K. Stock, Reg. No. 45, 899  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Customer No. **30623**

TRA 1963866v1